Azitromicina

Zitromax e altri

Bibliografia - Quali fonti bibliografiche per Azitromicina?

1. Adverse Drug Reaction Bulletin, 2013, n 212, edizione italiana.


2. Albert R.K. et al., NEJM, 2011, 365 (8), 689.


3. Altenburg J. et al., JAMA, 2013, 309 (12), 1251.


4. Amsden G.W. et al., J. Clin. Pharmacol., 2000, 40 (12 Pt 2), 1522.


5. Amsden GW. et al., J. Clin. Pharmacol., 2001, 41 (2), 210.


6. Anagnostopoulos G.K. et al., J. Clin. Gastroenterol., 2003, 36, 325.


7. Apseloff G.A. et al., J. Clin. Pharmacol., 1998, 36, 830.


8. Bergeron A. et al., JAMA, 2017, 318 (6), 557.


9. Cadle R.M. et al., Ann. Pharmacother., 1997, 31, 1308.


10. Cercek B. et al., Lancet, 2003, 361 (9360), 809.


11. Clin Pharmacokinet., 2000, 38 (3), 260.


12. Corriere Medico, 1991, 21-22 Novembre.


13. Curatolo W. et al., Pharm. Res., 2011, 28 (7), 1531.


14. Dietz A. et al., Laryngorhinootologie, 1998, 77 (2), 111.


15. Drug Fut., 2000, 25 (1), 77.


16. European Medicines Agency – EMA, Changes to the use of antibiotic azithromycin, 2025, 23 May https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_en.pdf


17. Equi A et al., Lancet, 2002, 360, 978.


18. FDA, Safety Announcement, 2013, 12 marzo disponibile on line http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm


19. Foulds G. et al., J. Clin. Pharmacol., 1991, 31, 164 e 859.


20. Gardner M.J. et al., Mediterranean Congress Chemotherapy, maggio 1992, Atene (abst.).


21. Goodman & Gilman, Le Basi Farmacologiche della Terapia, 1997, nona edizione, McGraw-Hill.


22. Gordillo M.E. et al., Antimicrob. Agents Chemother.,1993, 37,1203.


23. Grayston J.T. et al., NEJM, 2005, 352 (16), 1637.


24. Greenblatt D.J. et al., Clin. Pharmacol. Ther., 1998, 64 (3), 278.


25. Grunden J.W. et al., Ann. Pharmacother., 1997, 31, 859.


26. Hamilton-Miller J.M.T., J. Antimicrob. Chemother.,1992,29,141.


27. Hammerschlag M.R. et al., Pediatr. Infect. Dis., 1998, 17, 1049.


28. Handsfield H.H. et al., Sex Trans Dis, 1995, 274, 545.


29. Harris S. et al., Clin. Pharmacol. Ther., 1995, 58 (3), 310.


30. Hooton T.M., Am. J. Med., 1991, 91 Suppl. 3A, 23S.


31. Hubern C. et al., Lancet, 1997, 350, 563.


32. Jacobsson S. et al., Lancet Regional Health, 2025, vol 54, 101318 https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762%2825%2900110-3/fulltext


33. Khosropour C.M. et al., NEJM, 2014, 370 (20), 1961.


34. Kintzel P.E., Ann. Pharmacother., 1998, 32, 388.


35. Lane G. et al., Ann. Pharmacother., 1996, 30, 884.


36. Ljutic G., Rumboldt Z., Nephron, 1995, 70, 130.


37. Loewen P.S. et al., Drugs, 1999, 57, 157.


38. Luke D.R. et al., Antimicrob. Agents Chemother., 1996, 40, 2577.


39. Mansor G.A. et al., Ann. Intern. Med., 1993, 119, 636.


40. Martin D.H. et al., NEJM, 1991, 327, 921.


41. Martindale, The complate drug reference, 1999, 32 ed. Pharmaceutical Press.


42. MMWR Morb. Mortal Wkly Rep., 2013, 62 (6), 103.


43. Muhlestein J.B. et al., Circulation, 2000, 102 (15), 1755.


44. O’Connor C.M. et al., JAMA, 2003, 290 (11), 1459.


45. Pai M.P. et al., Ann. Pharmacother., 2000, 34 (4), 495.


46. Pinto L.A. et al., J. pediatr., 2012, 161 (6), 1104.


47. Pollak P.T. et al., Pharmacotherapy, 1997, 17, 827.


48. Ray W.A. et al., NEJM, 2012, 366 (20), 1881.


49. Salomon A.W. et al , NEJM, 2004, 351, 1962.


50. Scaglione F., Fraschini F., Medico e Paziente, 1990, 11, 84.


51. Svanstrom H. et al., NEJM, 2013, 368, 1704.


52. Ten Eick A.P. et al., Clin. Drug Invest., 2000, 20, 61


53. Thalhammer F. et al., Br. J. Clin. Pharmacol., 1998, 45 (1), 91.


54. The Medical Letter, 1999, 22, 95.


55. The Medical Letter, 2000, 12, 53.


56. Trifirò G. et al., CMAJ, 2017, 189 (15), E560.


57. Wallace M.R. et al., Lancet, 1994, 343, 241.


58. Wright A.J. et al., CMAJ, 2011, 183 (3), 303.


59. Young L.S. et al., Lancet, 1991, 338, 1107.